BIOCROSSROADS IS ADVANCING
A CATALYTIC STATE
We implement our mission by connecting with corporate, academic and philanthropic partners; facilitating investments in promising start ups and building new enterprises; and educating through conferences, reports and market development knowledge.
BIOCROSSROADS IS A CATALYST
FOR LIFE SCIENCES IDEAS
By partnering with Indiana’s research institutions, global companies, philanthropic organizations and government to advance growth and innovation, we make connections for all of Indiana’s life sciences community and work to accelerate its success.
A Top Region for Life Sciences Activity
Indiana is one of the top regions in the U.S. for life sciences activity. It boasts statistics that rival coastal hubs of activity and has gained national recognition for leadership in the life sciences. BioCrossroads seized an opportunity to do more with the state’s life sciences corporate and academic assets and bolster tremendous growth to the sector by building unique collaborations, marketing its strengths, igniting a capital market, moving research from laboratory to the patient, and developing a one-of-a-kind institute to accelerate research and commercialization.
The result is a vibrant and uniquely collaborative life sciences state-wide community with a $78 billion economic impact. The magic combination of Indiana’s depth and breadth of life sciences resources together with BioCrossroads’ continuing ability to harness those assets into actionable outcomes like the organization of venture funds, the Indiana Biosciences Research Institute development, and the generation of other unique private-public partnerships is unprecedented and has secured a strategy for Indiana’s economic future as well as for the health of its citizens and the rest of the world.
BIOCROSSROADS’ IMPACT ON
INDIANA’S LIFE SCIENCES SECTOR
Indiana Future Fund (IFF) - $73M
BioStorage, Colucid, Endocyte
Largest life sciences networking and conference in Indiana
12M patient records
Attract, engage, and retain young professionals
200+ T2D and Cardiac patient samples and clinical data
K-12 Education and Professional Development
Indiana Seed Fund I - $6M
Sports Injury surveillance for youth, high school and college athletes
INext - $58M
Bicycle Therapeutics, Relypsa, Arteaus
Warsaw based industry/community engagement
Indiana Seed Fund II - $8.25M
MB2, Calibrium, Assembly Biosciences, Anagin
Industry-organized research institute focused on metabolic disease and nutrition
Statewide agbiosector innovation initiative
Hub for BioCrossroad's educational offerings and events
60-acre place-based innovation strategy for advanced industries and talent
Indiana Seed Fund III - $9M
Scioto Biosciences, AniDyn
MEET OUR TEAM
BOARD OF DIRECTORS
Brenda Bratton joined BioCrossroads in January 2005 as Executive Assistant for David Johnson, President and CEO. Previously she worked at the law firm of Baker & Daniels for 15 years.
Brian Stemme is project director for BioCrossroads. He has a strong background in life sciences market development and research. He is responsible for identifying and developing opportunities for growth within Indiana’s life sciences sector, evaluating early-stage companies for investment by BioCrossroads’ seed funds and supporting the State’s efforts to attract and grow life sciences companies.
Brian led the formation of the Central Indiana Corporate Partnership’s AgriNovus Indiana, a nonprofit established in 2013 to leverage Indiana’s strengths in agricultural innovation, working with industry CEOs, Indiana’s Lieutenant Governor and Purdue University to launch the new entity, publish a first-of-its-kind report and support early-stage ag-tech companies.
He is a member of the board of directors of Allinaire Therapeutics and Scioto Biosciences.
Prior to joining BioCrossroads, Brian was employed by Eli Lilly and Company in Corporate Affairs, where he ran the company’s political action committee. He also worked as a Senior Analyst in the company’s biotechnology unit and was a member of the team that established Lilly Systems Biology, Ltd. in Singapore. Previously, Brian was a manager in Arthur Andersen’s Assurance practice, providing audit and tax consulting to companies in the energy, software and healthcare industries.
Brian is a Butler University graduate and a member of its Board of Trustees.
Chris serves as project director for BioCrossroads. In this capacity, Chris focuses on promoting the entrepreneurial and institutional opportunities throughout Indiana’s life science community. He manages the BioCrossroads New Venture Competition and supports the Indiana Biosciences Research Institute, the 16 Tech Innovation District and OrthoWorx. Chris also serves as an advisor to the Indiana Seed Fund II and assists the fund manager in deal sourcing, diligence and execution of portfolio investments. He currently serves on the board of the Datalys Center for Sports Injury Research and Prevention.
Prior to joining BioCrossroads, Chris spent several years as the Director of Life Sciences for the Indiana Economic Development Corporation, where he led the state’s initiative to expand, attract, and retain life sciences corporations. He served on the board of directors for Indiana Health Information Technology, Inc. and the Indiana Cord Blood Bank. Previously, he also oversaw Indiana’s Health and Human Service agencies while at the Office of Management and Budget.
Chris earned a BS in Biology from Yale University, where he was a two-time Academic All-American, and an MBA from the Krannert School of Management at Purdue University
DAVID L. JOHNSON
David L. Johnson was elected President and CEO of the Central Indiana Corporate Partnership (CICP) in December 2012. CICP is a unique strategic collaboration of business leaders and university presidents organized to develop initiatives, investments and projects that advance regional prosperity. Since 2005, Johnson has also served as President and CEO of CICP’s BioCrossroads life sciences initiative.
Johnson has been engaged with CICP for more than a decade as one of the founders of BioCrossroads, a market-based enterprise focused on strategic collaborations and investments for growing Indiana’s substantial life sciences sector. Among its many activities, BioCrossroads informs and educates; raises and invests venture capital funds in promising new companies; and builds collaborations of key partners from academia and industry. Through his work at BioCrossroads, Johnson has been responsible for raising over $350 million dollars in philanthropic, corporate and venture capital funding.
Johnson is an honors graduate of Harvard University, Harvard Law School and Oxford University, where he studied as a Rhodes Scholar.
Julie serves as the office manager for BioCrossroads, a role she has held since 2003. Prior to joining the organization, Julie worked at the Indy Partnership, the City of Indianapolis Mayor’s Office and the Indianapolis Zoo.
In addition, Julie serves as the membership manager and executive assistant to the COO for the Central Indiana Corporate Partnership. In her position as membership manager, Julie serves as the liaison to the members of CICP and handles the coordination of meetings and events for the members.
She is a graduate of Trine University in Angola, Ind.
Lori LeRoy is the Vice President of Communications for BioCrossroads and also serves in the same role at the Central Indiana Corporate Partnership, an organization that includes the chief executives of Central Indiana’s prominent corporations and university presidents in a strategic and collaborative effort dedicated to the region’s continued prosperity and growth. BioCrossroads is CICP’s sector initiative for the life sciences. She leads all public relations, marketing, advertising, and event development for both organizations.
LeRoy was previously marketing manager, communications for Roche Diagnostics Diabetes Care business area. She was also a public relations consultant at Roche where she managed product public relations for its laboratory, hospital, physician’s office and research products. With a strong background in consumer PR, brand awareness campaigns and health care/technology PR, she has also held positions as senior manager, corporate communications at Philips Consumer Electronics and corporate communications manager at AirTran Airways.
She earned a B.A. in English and Asian Studies from Oglethorpe University in Atlanta, where she also served as a member of the Alumni Association Board of Directors.
Nora Doherty joined BioCrossroads in 2003 after working many years with entrepreneurial companies. She is senior vice president for BioCrossroads and managing director for its Seed Funds. In this role, she directs activities of nearly $24M assets under management for use in early stage investment in life sciences companies having completed investments in over two dozen companies including SonarMed, Calibrium, Assembly (ASMB), Anagin, and Scioto Biosciences. Doherty has also overseen many BioCrossroads research and publications including Advancing Indiana’s Life Sciences Competitive and Strategic Collaborations; Impact of Talent on Innovation: Indy’s Talent Dynamics; and Impact of Research Institutions on Regional Economies, among others.
Doherty has a history of working for entrepreneurial companies. She was vice president of Electronic Evolutions and a co-founder, vice president of Operations and vice president Legal, Human Resources and Administration, and corporate secretary with Escient Technologies. Escient Technologies managed numerous consumer electronic and internet related businesses, including Gracenote® which was purchased by Sony in 2008.
Doherty received her BA and MBA from Indiana University, where she was a member of the honors program. She also received the “Excellence in Leadership” award as special recognition from the professors and administration of Indiana University MBA-CIP for leadership and contribution to the program.
VANESSA BARTH, Ph.D.
Vanessa Barth, Ph.D. is Chief Scientific Officer for BioCrossroads and a loaned executive from Eli Lilly. She brings 19 years of industrial experience with a strong emphasis in cross-functional collaboration in both scientific and operational arenas. In her current role, Vanessa focuses on operational and strategic opportunities for BioCrossroads, including entrepreneurial support and programming activities, inclusive talent and workforce development programs, and K12 STEM education programs. In addition, she works on collaborative projects with the Indiana Biosciences Research Institute and 16 Tech Innovation Community.
Most recently, Vanessa served as senior director at Eli Lilly and Company in Lilly Research Laboratories and was responsible for Strategic Completive Intelligence & Scientific Support. This role included building a diverse, inclusive team of competitive intelligence professionals that developed strategy and decision-making associated with therapeutic and functional business areas in support of the research portfolio. She also led the reshaping of Lilly Research Laboratories outsourcing.
Prior to moving in to operations, she led the tracer discovery and receptor occupancy efforts for Lilly Research Laboratories.
Vanessa received her Bachelor of Arts degree in neuroscience from Pomona College, The Claremont Colleges and her Ph.D. in medical neurobiology from Indiana University. She also holds certificates in business (Harvard), competitive intelligence (Academy of Competitive Intelligence), and (International Business Innovation Association).
Patricia (Patty) Martin joined BioCrossroads as the president and CEO in July 2019. A former Eli Lilly and Company executive, she was the chief operating officer (COO) of Lilly Diabetes for seven years as well as served as Lilly’s Chief Diversity Officer (CDO) and Chief Alliance Officer (CAO). In her 25-year career at Lilly, she also had leadership roles that included strategy, clinical product development, and investor relations.
Martin’s background is a unique breadth of experience integrating science and business. As COO of Lilly Diabetes, she was part of a leadership team that established a vision and strategy that uniquely addressed the increased prevalence and diverse needs of people living with diabetes. During her tenure, Lilly Diabetes launched an unprecedented six new products in 18 months, increasing sales from $6 billion to $8 billion. As CAO, she spearheaded collaborative efforts to ensure the success of Lilly’s partnerships and facilitated cross-functional and cross-disciplinary cooperation to deliver results.
Martin serves on the board of directors of CareSource, Inc. and UltiMed, Inc.
Actively involved in Indianapolis and national non-profit organizations, she is currently a member of the Indiana University Women’s Philanthropy Leadership Council; member of the board of trustees of the Christian Theological Seminary; the Dean’s Advisory Council for the Indiana University Kelley School of Business; and was the board chair for the 500 Festival in 2016. She also serves a board member of the Diabetes Patient Advocacy Coalition.
A graduate of Indiana University, Martin also earned her MBA from the Harvard School of Business.